Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-04-05
2011-04-05
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S158100, C514S912000
Reexamination Certificate
active
07919094
ABSTRACT:
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4394370 (1983-07-01), Jefferies
patent: 4526909 (1985-07-01), Urist
patent: 4563489 (1986-01-01), Urist
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4975527 (1990-12-01), Koezuka et al.
patent: 5211657 (1993-05-01), Yamada et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5552157 (1996-09-01), Yagi et al.
patent: 5565213 (1996-10-01), Nakamori et al.
patent: 5567434 (1996-10-01), Szoka
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5610288 (1997-03-01), Rubenstein
patent: 5693762 (1997-12-01), Queen et al.
patent: 5718709 (1998-02-01), Considine et al.
patent: 5738868 (1998-04-01), Shinkarenko
patent: 5739119 (1998-04-01), Galli et al.
patent: 5741516 (1998-04-01), Webb et al.
patent: 5759829 (1998-06-01), Shewmaker et al.
patent: 5789573 (1998-08-01), Baker et al.
patent: 5795587 (1998-08-01), Gao et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6420432 (2002-07-01), Demopulos et al.
patent: 6492332 (2002-12-01), Demopulos et al.
patent: 6645168 (2003-11-01), Demopulos et al.
patent: 6649592 (2003-11-01), Larson
patent: 6969601 (2005-11-01), Jensenius et al.
patent: 7060267 (2006-06-01), Jensenius et al.
patent: 7083786 (2006-08-01), Jensenius et al.
patent: 7112414 (2006-09-01), Jensenius et al.
patent: 2002/0019369 (2002-02-01), Li et al.
patent: 2002/0082208 (2002-06-01), Jensenius et al.
patent: 2002/0082209 (2002-06-01), Jensenius et al.
patent: 2002/0094332 (2002-07-01), Bell
patent: 2003/0049260 (2003-03-01), Bell
patent: 2003/0207309 (2003-11-01), Hageman et al.
patent: 2004/0038297 (2004-02-01), Jensenius et al.
patent: 2004/0081619 (2004-04-01), Bell
patent: 2004/0219147 (2004-11-01), Bell
patent: 2004/0259771 (2004-12-01), Stahl et al.
patent: 2005/0004031 (2005-01-01), Subasinghe et al.
patent: 2005/0222027 (2005-10-01), Chiang et al.
patent: 2006/0002937 (2006-01-01), Schwaeble et al.
patent: 2006/0018896 (2006-01-01), Schwaeble et al.
patent: 2006/0275764 (2006-12-01), Thiel et al.
patent: 2007/0009528 (2007-01-01), Larsen et al.
patent: 2007/0031420 (2007-02-01), Jensenius et al.
patent: 0 321 201 (1994-12-01), None
patent: WO 95/23161 (1995-08-01), None
patent: WO 00/35483 (2000-06-01), None
patent: WO 01/07067 (2001-02-01), None
patent: WO 01/12212 (2001-02-01), None
patent: WO 02/06460 (2002-01-01), None
patent: WO 03/009803 (2003-02-01), None
patent: WO 03/061765 (2003-07-01), None
patent: WO 03/063799 (2003-08-01), None
patent: WO 2004/009664 (2004-01-01), None
patent: WO 2004/022096 (2004-03-01), None
patent: WO 2004/050907 (2004-06-01), None
patent: WO 2004/075837 (2004-09-01), None
patent: WO 2004/106384 (2004-12-01), None
patent: WO 2005/002627 (2005-01-01), None
patent: WO 2005/024013 (2005-03-01), None
patent: WO 2005/120222 (2005-12-01), None
Takahashi et al., J. Exp. Med. vol. 207 No. 1, pp. 29-37.
Shoji et al., Current Pharmaceutical Design, 2004, 10, 785-796.
Khan et al., J Biomed Sci 2003;10:457-467.
Ziwei Huang, Pharmacol Ther. Jun. 2000;86(3):201-15.
Ambrus, G., et al., “Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and —2: A Study on Recombinant Catalytic Fragments,”The Journal of Immunology 170:1374-1382 (2003).
Amsterdam, E.A., et al., “Limitation of Reperfusion Injury by a Monoclonal Antibody to C5a During Myocardial Infarction in Pigs,”American Journal of Physiology 268:H448-H457 (1995).
Baelder, R., et al., “Pharmacological Targeting of Anaphylatoxin Receptors During the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation,”The Journal of Immunology 174:783-789 (2005).
Baldwin, W.M., et al., “Complement in Transplant Rejection: Diagnostic and Mechanistic Considerations,”Springer Seminars in Immunopathology 25:181-197 (2003).
Banda, N. K., et al., “Prevention of Collagen-Induced Arthrtitis in Mice Transgenic for the Complement Inhibitor Complement Receptor 1-Related Gene/Protein y1,”The Journal of Immunology 171:2109-2115 (2003).
Barnum, S.R., “Complement in Central Nervous System Inflammation,”Immunologic Research 26(1-3):7-13 (2002).
Bartlow, B.G., et al., “Nonimmunoglobulin C3 Activating Factor in Membranoproliferative Glomerulonephritis,”Kidney International 15:294-302 (1979).
Bone, R.C., et al., “Definitions for Sepsis and Organ Failure,”Critical Care Medicine 20(6):724-726 (1992).
Bora, P.S., et al., “Role of Complement and Complement Membrane Attack Complex in Laser-Induced Choroidal Neovascularization,”The Journal of Immunology 174:491-497 (2005).
Brandt, J., et al., “Role of the Complement Membrane Attack Complex (C5b-9) in Mediating Experimental Mesangioproliferative Glomerulonephritis,”Kidney International 49:335-343 (1996).
Brenchley, P.E., et al., “Urinary C3dg and C5b-9 Indicate Active Immune Disease in Human Membranous Nephropathy,”Kidney International 41:933-937 (1992).
Campbell, L.A., et al., “Detection ofChlamydia pneumoniaeTWAR in Human Coronary Atherectomy Tissues,”The Journal of Infectious Diseases 172:585-588 (1995).
Casanova, J.-L., and L. Abel, “Human Mannose-binding Lectin in Immunity: Friend, Foe, or Both?”The Journal of Experimental Medicine 199(10):1295-1299 (2004).
Celik, I., et al., “Role of the Classical Pathway of Complement Activation in Experimentally Induced Polymicrobial Peritonitis,”Infection and Immunity 69(12):7304-7309 (2001).
Chai, P.J., et al., “Soluble Complement Receptor-1 Protects Heart, Lung, and Cardiac Myofilament Function From Cardiopulmonary Bypass Damage,”Circulation 101:541-546 (2000).
Chen, C.-B., and R. Wallis, “Stoichiometry of Complexes Between Mannose-Binding Protein and Its Associated Serine Proteases,”The Journal of Biological Chemistry 276(28):25894-25902 (2001).
Chenoweth, D.E., “Complement Activation in Extracorporeal Circuits,”Ann. N.Y. Acad. Sci. 516:306-313 (1987).
Cheung, A.K., “Biocompatibility of Hemodialysis Membranes,”Journal American Soc. Nephrol. 1(2):150-161 (1990).
Collard, C.D., et al., “Complement Activation After Oxidative Stress: Role of the Lectin Complement Pathway,”American Journal of Pathology 156(5):1549-1556 (2000).
Collard, C.D., et al., “Endothelial Oxidative Stress Activates the Lectin Complement Pathway,”American Journal of Pathology 159(3):1045-1054 (2001).
Connolly, A.M., et al., “Complement 3 Deficiency and Oral Prednisolone Improve Strength and Prolong Survival of Laminin α2-Deficient Mice,”Journal of Neuroimmunology 127:80-87 (2002).
Couser, W.G., et al., “The Effects of Soluble Recombinant Complement Receptor 1 on Complement-Mediated Experimental Glomerulonephritis,”Journal American Soc. Nephrol. 5(11):1888-1894 (1995).
Craddock, P.R., et al., “Complement and Leukocyte-Mediated Pulmonary Dysfunction in Hemodialysis,”The New England Journal of Medicine 296(14):769-774 (1977).
Cuchacovich, M., et al., “Potential Pathogenicity of Deglycosylated IgG Cross Reactive With
Fujita Teizo
Parent James B
Schwaeble Hans-Wilhelm
Stover Cordula Margaret
Tedford Clark E
Christensen O'Connor Johnson & Kindness PLLC
Omeros Corporation
Skelding Zachary
University of Leicester
LandOfFree
Methods for treating conditions associated with MASP-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating conditions associated with MASP-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating conditions associated with MASP-2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2715163